CLYM Q3 2023 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$4M

EPS (Diluted)

$-0.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$656,000

Balance Sheet

Total Assets

$113M

Total Liabilities

$3M

Stockholders' Equity

$110M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$9M	+42.8%
Net Income	-$4M	-$10M	+59.0%